{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"95"}]}],"title":"Hematology: Absolute Neutrophils Counts (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"42"}]}],"title":"Hematology: Hemoglobin (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"78"}]}],"title":"Hematology: Platelets (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"103"}]}],"title":"Hematology: Any hemoglobin, platelet, or ANC decrease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"26"}]}],"title":"Chemistry: Alanine Transaminase (ALT) (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"30"}]}],"title":"Chemistry: Aspartate Aminotransferase (AST) (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"21"}]}],"title":"Chemistry: Alkaline Phosphatase (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"25"}]}],"title":"Chemistry: Bilirubin (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"17"}]}],"title":"Chemistry: Creatinine (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"17"}]}],"title":"Chemistry: Creatinine Clearance (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}]}],"title":"Chemistry: Hypercalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"20"}]}],"title":"Chemistry: Hypoalbuminemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"30"}]}],"title":"Chemistry: Hypocalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"title":"Chemistry: Phosphate (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"9"}]}],"title":"Chemistry: Potassium (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"22"}]}],"title":"Chemistry: Potassium (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"}]}],"title":"Chemistry: Sodium (Decrease)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"}]}],"title":"Chemistry: Sodium (Increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"19"}]}],"title":"Chemistry: Uric Acid (Increase)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) were reported.","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"},{"description":"Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG001","title":"Treatment Arm B (Chlorambucil + Obinutuzumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set is defined as all randomized participants who received at least one dose of any one of the four study drugs (ibrutinib, venetoclax, chlorambucil, or obinutuzumab).","reportingStatus":"POSTED","timeFrame":"Up to 4 years 10 months","title":"Number of Participants With Abnormal Clinical Laboratory Findings","type":"SECONDARY","unitOfMeasure":"Participants"}